Table 2.
VB12 (EE %) | Antipyrine (EE %) | 2-DG (EE %) | Glucose (mM) | |||||
---|---|---|---|---|---|---|---|---|
Probe | DPP | CP | DPP | CP | DPP | CP | DPP | CP |
Day 0 | 26±3 | 29±4 | 56±7 | 59±6 | 53±12 | 53±11 | 4.8±0.6 | 4.4±0.8 |
Day 3 | 21±2 | 19±3 * | 61±7 | 57±5 | 54±7 | 51±8 | 3.6±0.8 | 3.8±0.7 |
Day 4 | 17±7 | 62±5 | 53±6 | 3.1±1.0 * | ||||
Day 5 | 17±7 | 59±3 | 52±13 | 2.9±1.0 * | ||||
Day 6 | 13±10 ** | 58±7 | 52±11 | 2.0±1.3** | ||||
Day 7 | 11±6 **† | 9±5 **† | 58±4 | 54±3 | 49±7 | 49±8 | 1.3±0.5**† | 1.5±1.2**† |
Two PC microdialysis probes were implanted per rat into the dorsal subcutaneous space, n=6 rats. The control probe (CP) was perfused with 100 µM VB12, 100 µM antipyrine and 5 mM 2-DG on day 0, day 3 and day 7 at 1 µL/min. Samples were collected every 30 min for 3 hrs (n=6). The daily-perfused probe (DPP) was perfused with the same solutions on day 0 and day 3 through day 7. Data represent mean ± SD, n=6 (average of 6 samples from 6 rats).
Significant differences from Day 0 at the p< 0.05
and p < 0.01 were determined using the repeated measurements of ANOVA.
denotes p <0.001 as compared to Day 0 (acute day) using non-parametric repeated ANOVA.